Our Mission
Our focus is strong.
We are committed to using our technology to improve health outcomes for all, not just for those who can afford it. Too often, marginalised or vulnerable populations are denied access to medical technology that could improve their quality of life or even save them from life-threatening disease. At Benignancy, we pride ourselves at making cutting-edge novel technologies that are widely accessible.
Our mission is threefold.
-
Firstly...
The introduction of novel therapies in Otolaryngology, Head and Neck Surgery using an individualised, patient-centric model to facilitate improved outcomes and a better quality of life for patients.
-
Second...
The establishment of sophisticated, local manufacturing facilities employing and encouraging Australian involvement in biotechnology.
-
& Third...
The acknowledgement of our collective social responsibility to Indigenous Australians and other marginalised groups to better treat the common problems faced by these communities.
The impact.
Head and neck cancer (HNC) is the 7th most common cancer in Australia and globally, with causes and burdens that are dynamic, significant and growing.
Globally, Head and Neck Cancer accounts for 5.3% of all new cancer cases (600,000) and deaths (300,000) each year. In Australia and the U.S. HNC accounts for approximately 3.6-4% of cases and 2.4% of cancer deaths. The projected cost (USD) of HNC in 2020 in the U.S. is between $3.79 billion and $5.46 billion. In advanced economies like Australia, hospital and treatment costs per individual are $14,391 per month, with a median of 95 days of treatment of lost income, a 15-17% reduction in future earnings and unquantifiable social costs.